Seamflow raises $4.5M to ease Europe’s medtech backlog
London-based startup Seamflow has secured $4.5 million in funding to address one of Europe’s most pressing healthcare bottlenecks: the 20‑month average approval time for new medical devices under the European Union’s Medical Device Regulation (MDR).
The company is building a specialised regulatory workflow platform designed to help manufacturers, consultants and Notified Bodies prepare, review and manage complex conformity assessments far more efficiently. The fresh capital will be used to expand product development, deepen integrations with existing compliance tools and scale operations across the EU market.
Fixing a costly regulatory logjam
Since the full rollout of the MDR, European medtech firms have faced a sharp rise in documentation requirements, clinical evidence standards and post‑market surveillance obligations. This has created a severe capacity crunch at Notified Bodies and left many innovative devices stuck in the approval queue for over a year and a half.
Seamflow aims to shorten that cycle by centralising regulatory data, automating repeatable tasks and guiding teams through MDR‑specific requirements. Its platform uses structured templates, version control and real‑time collaboration tools to reduce errors and rework, which are among the main causes of prolonged review times.
Digitising compliance for medtech innovators
Instead of relying on spreadsheets, email threads and fragmented document repositories, manufacturers can use Seamflow as a single system of record for technical documentation, clinical evaluation reports and risk management files. The startup is also working on analytics features that help companies anticipate regulator feedback and benchmark their progress against similar submissions.
Industry observers say tools like Seamflow could play a critical role in keeping Europe attractive for medtech innovation. Long and unpredictable approval timelines have already prompted some companies to prioritise the US or other markets. If the platform can materially reduce preparation and review time, it could accelerate patient access to new technologies while easing the workload on overstretched regulators.
With its new funding, Seamflow is positioning itself as a core part of the digital infrastructure needed to make the EU’s stricter safety rules workable for both startups and established device makers.